139 related articles for article (PubMed ID: 8990622)
1. Cytokine therapy for hematological malignancies.
Ezaki K
Int J Hematol; 1996 Dec; 65(1):17-29. PubMed ID: 8990622
[TBL] [Abstract][Full Text] [Related]
2. Cytokine therapy for hematological malignancies.
Ezaki K; Tsuzuki M
Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():182-94. PubMed ID: 9210900
[TBL] [Abstract][Full Text] [Related]
3. Cytokines in the treatment of hematological disorders: recent progress and perspectives.
Robak T
Arch Immunol Ther Exp (Warsz); 1996; 44(1):5-9. PubMed ID: 8874763
[TBL] [Abstract][Full Text] [Related]
4. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
5. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review.
Geller RB
J Clin Oncol; 1996 Apr; 14(4):1371-82. PubMed ID: 8648396
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of colony-stimulating factors in acute leukemia.
Holdsworth MT; Mathew P
Ann Pharmacother; 2001 Jan; 35(1):92-108. PubMed ID: 11197591
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
9. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
10. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
11. The use of myeloid colony-stimulating factors in hematologic malignancies: the role of systematic reviews and meta-analyses.
Gurion R; Shacham-Abulafia A; Shpilberg O; Raanani P
Acta Haematol; 2011; 125(1-2):68-79. PubMed ID: 21150189
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group.
Ogura M; Kagami Y; Suzuki R; Miura K; Uehira K; Kurokawa T; Ito T; Kinoshita T; Emi N; Morishima Y; Kodera Y; Ueda R
Cancer Chemother Pharmacol; 1997; 40 Suppl():S51-7. PubMed ID: 9272135
[TBL] [Abstract][Full Text] [Related]
13. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
15. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.
Gurion R; Belnik-Plitman Y; Gafter-Gvili A; Paul M; Vidal L; Ben-Bassat I; Shpilberg O; Raanani P
Cochrane Database Syst Rev; 2011 Sep; (9):CD008238. PubMed ID: 21901718
[TBL] [Abstract][Full Text] [Related]
16. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
18. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
Ghalaut PS; Sen R; Dixit G
J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
20. Proliferative reaction of myelogenous leukemia cells with cytokines G-CSF, GM-CSF, M-CSF, SCF and TPO.
Murayama T; Imoto S; Natazuka T; Chihara K; Matsui T
Leuk Res; 1998 Jun; 22(6):557-60. PubMed ID: 9678722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
